rss
Arch Dis Child Fetal Neonatal Ed 2005;90:F294-FF300 doi:10.1136/adc.2004.056317
  • Original article

Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis

  1. E Nestaas1,2,
  2. H-J Bangstad2,
  3. L Sandvik3,
  4. K-O Wathne2
  1. 1Department of Paediatrics, Hospital of Vestfold, Tønsberg, Norway
  2. 2Department of Paediatrics, Ullevål University Hospital, Norway
  3. 3Centre for Clinical Research, Ullevål University Hospital
  1. Correspondence to:
    Dr Nestaas
    Department of Paediatrics, Hospital of Vestfold, PO Box 2168, Tønsberg 3103, Norway; eirikpdastart.no
  • Accepted 19 January 2005
  • Published Online First 27 April 2005

Abstract

Objectives: To review the evidence from controlled clinical trials of neonates given equal daily aminoglycoside doses as extended interval dosing (dosage interval typically 24 hours in term and 36–48 hours in immature neonates) compared with traditional dosing (dosage interval typically 8–12 hours in term and 12–24 hours in immature neonates).

Design: Systematic review and meta-analysis of controlled trials found in electronic databases, trial registers, and references in reviews and selected trials.

Settings: The selected trials were blinded and assessed for methodological quality. Each trial’s own predefined criteria for treatment failure, nephrotoxicity, ototoxicity, and therapeutic serum drug concentrations were used.

Subjects: Controlled trials of neonatal aminoglycoside treatment in which equal aminoglycoside daily doses were given at traditional and extended dosage intervals.

Main outcome measures: Serum drug concentrations outside the therapeutic range. Treatment failure and toxicity.

Results: Sixteen trials involving 823 neonates met the inclusion criteria for the systematic review. Twelve trials involving 698 neonates were included in the meta-analysis of the pharmacokinetics. Compared with traditional dosing, extended interval dosing was associated with a significantly lower risk of both peak (summary risk ratio 0.50, 95% confidence interval 0.26 to 0.94) and trough (0.36, 0.25 to 0.56) serum drug concentrations outside the therapeutic range. Accurate information on treatment failure was obtained in nine trials involving 555 neonates. One trial reported treatment failure. In this trial two neonates in the traditional dosing group did not respond to treatment within 72 hours. Nephrotoxicity was investigated in 589 neonates in 12 trials and ototoxicity in 210 neonates in four trials, with no significant differences between the two dosing regimens.

Conclusions: Extended interval dosing of aminoglycosides in neonates is safe and effective, with a reduced risk of serum drug concentrations outside the therapeutic range.

Footnotes

  • Published Online First 27 April 2005

  • Funding: EN has received funding for statistics courses from the Sister Strays legacy.

  • Competing interests: none declared

Responses to this article

  • Gentamicin and Amikacin: extended interval dosing in neonates.
    • Paulo Arturo Caceres Guido,
    • Bramuglia G, Travaglianti M, Castro G.
    Arch Dis Child - Fetal Neonatal Ed published online June 5, 2006
  • Aminoglycoside extended interval dosing in neonates is safe and effective.
    • Eirik Nestaas
    Arch Dis Child - Fetal Neonatal Ed published online April 3, 2006
  • Single daily dose aminoglycosides in the neonatal period appear to be effective: but are they safe?
    • Peter M Loughnan,
    • Nil
    Arch Dis Child - Fetal Neonatal Ed published online July 20, 2005

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. Web-only appendix
  5. All versions of this article:
    1. adc.2004.056317v1
    2. 90/4/F294 most recent

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.